
|Articles|April 17, 2006
Advances in treatment of MI reported at ACC show
The low molecular weight heparin enoxaparin (Lovenox, Sanofi-Aventis) is superior to unfractionated heparin as an adjunct to thrombolytic therapy in patients with ST elevation myocardial infarction (MI), researchers reported at the 55th Annual Scientific Session of the American College of Cardiology (ACC). The meeting was held in Atlanta last month.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide
2
White House Announces Action to Increase Competition, Decrease Cost of Biosimilar Development
3
FDA Approves Mirikizumab as Once Monthly Injection for Moderately to Severely Active Ulcerative Colitis
4
American Pharmacists Month: Clinical Service Expansion Benefits Patient Outcomes, Pharmacist Profession
5


























































































































































